Xarelto side effects include bloods clots, bleeding, and stroke. Our law firm is currently working with experienced lawyers, who can file a Xarelto lawsuit, and there are no legal fees unless you receive a settlement or award. Feel free to contact us online or call us toll-free anytime.
Xarelto (rivaroxaban) is blood thinner and it is the first “direct Xa inhibitor” taken orally. In June 2011, the FDA approved the medicine for sale on the market. It is manufactured by Bayer but marketed by Janssen Pharmaceuticals. Xarelto is an anticoagulant which means it prevents blood from clotting. These types of medicines are often used to prevent or treat deep vein thrombosis, atrial fibrillation, pulmonary embolism, stroke, and other conditions. However, there is no way to reverse the anticoagulant effect of Xarelto in the case of a major bleeding event like gastrointestinal hemorrhage, cerebral hemorrhage, or intracranial hemorrhage.
Xarelto Side Effects
Blood thing drugs have been associated with bleeding complications. For example, Xarelto patients take the medicine either once or twice a day. The effects of the drug last 8-12 hours and the body’s Xa activity does not return to normal until after 24 hours. This means that if a patient suffers a serious bleeding event this medicine may continue to prevent normal clotting for hours. If you have suffered serious side effects of Xarelto, then you should talk to a personal injury lawyer.
- Blood clots
- Gastrointestinal hemorrhage
- Spinal hemorrhage
- Intracranial hemorrhage
- Epidural hemorrhage
- Cerebral hemorrhage
Adverse Events and Medical Studies
The FDA has received a number of adverse event reports regarding Xarelto and medical studies have examined the safety of this drug. In September 2011, the New England Journal of Medicine published the ROCKET-AF study, which compared the medicine to Warfarin in patients suffering from atrial fibrillation. The study concluded that “there was not significant between-group difference in the risk of major bleeding” (i).
In June 2012, an FDA advisory panel voted against approving this medicine for the treatment of acute coronary syndrome. The primary concern raised by the panel was the fact that 15% of study participants dropped out of the Phase 3 ATLAS ACS 2 TIMI 51 study. Read The New York Times article here. Later that same year, the Institute for Safe Medication Practices (ISMP) issued its QuarterWatch report based on FDA data from the first quarter of 2012. During this period, the FDA received 356 adverse event reports of Xarelto side effects including “serious, disabling, or fatal injury.” Additionally, 158 reports indicated blood clots were the serious side effect (ii). More recently, in February 2013, the New England Journal of Medicine published the results of the MAGELLAN study, which found the Xarelto may carry an increased risk of bleeding (iii).
People who have been injured by this medicine, should talk to an attorney about filing a Xarelto lawsuit. Injuries are often caused by these types of medicines because the drug was defectively designed or the patient was not adequately warned about the drug’s dangers. One of the concerns with recent blood thinning medicines like Xarelto is that they have no antidote. This means that a patient may not be able to slow internal bleeding because the drug is still preventing clotting. Additionally, a patient may not have been warned that this was a real risk of the drug.
Do You Need Advice from a Xarelto Lawyer?
If you or a loved has been suffered serious bleeding injuries due to taking this medicine, then you should talk to an attorney about your legal options. You may be entitled to compensation for medical expenses, lost income, pain and suffering, or other losses. We work with some of the more experienced Xarelto Lawyers who handle these cases and there is no legal fee unless you receive a settlement or award. Feel free to call us toll-free anytime or submit a contact form online for a free legal consultation.
- (i) The New England Journal of Medicine, September 2011.
- (ii) Institute for Safe Medication Practices, QuaterWatch, October 3, 2012.
- (iii) The New England Journal of Medicine, February 2013.